Privately held Ginkgo Bioworks announces a project with mRNA vaccine developer Moderna (MRNA -2.2%) aimed at optimizing the latter’s processes for making key raw materials for its vaccines, including its COVID-19 candidate.
Ginkgo is contributing its platform infrastructure
and know-how to help Moderna to more quickly improve the efficiency of
its processes, adding that it has committed to providing $25M in free
work to support the effort.
https://seekingalpha.com/news/3560881-moderna-teams-up-ginkgo-bioworks-to-improve-manufacturing-processes
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.